MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-29-2025
NeoGenomics Book Value 2011-2026 | NEO
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value NeoGenomics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 902 M | 942 M | 998 M | 1.11 B | 694 M | 507 M | 320 M | 206 M | 187 M | 238 M | 60.4 M | 21.7 M | 9.22 M | 5.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.11 B | 5.9 M | 443 M |
Quarterly Book Value NeoGenomics
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 854 M | 888 M | 902 M | 908 M | 916 M | 923 M | 942 M | 947 M | 956 M | 974 M | 998 M | 1.01 B | 1.04 B | 1.08 B | 1.11 B | 1.14 B | 1.15 B | 844 M | 694 M | 694 M | 694 M | 694 M | 507 M | 507 M | 507 M | 507 M | 320 M | 320 M | 320 M | 320 M | 205 M | 205 M | 205 M | 205 M | 187 M | 187 M | 187 M | 187 M | 238 M | 238 M | 238 M | 238 M | 60.4 M | 60.4 M | 60.4 M | 60.4 M | 21.7 M | 21.7 M | 21.7 M | 21.7 M | 9.22 M | 9.22 M | 9.22 M | 9.22 M | 5.9 M | 5.9 M | 5.9 M | 5.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 B | 5.9 M | 458 M |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
14 M | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 23.56 | -2.04 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 33.99 | 0.65 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.38 | -6.12 % | $ 1.75 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
456 M | $ 39.01 | -0.38 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
86 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 218.94 | -0.24 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 102.48 | 0.18 % | $ 19 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 26.01 | -0.88 % | $ 786 M | USA |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-140 M | $ 111.89 | 1.28 % | $ 13.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
2.07 B | $ 73.26 | -1.0 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 20.4 | -1.92 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
116 M | $ 109.94 | -1.94 % | $ 4.34 B | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 10.95 | 6.31 % | $ 311 M | Israel |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 65.82 | -1.3 % | $ 4.55 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 145.95 | -2.5 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 230.03 | -2.31 % | $ 41.7 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 210.0 | -0.83 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
826 M | $ 583.39 | -1.63 % | $ 18.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 184.82 | 1.37 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 8.94 | -7.45 % | $ 1.16 B | USA |
 |
Personalis
PSNL
|
203 M | $ 9.4 | -5.72 % | $ 557 M | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
14.4 M | $ 24.39 | 0.54 % | $ 31.7 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.07 B | $ 269.39 | -0.16 % | $ 22.6 B | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 384.16 | -0.62 % | $ 29.4 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 179.07 | -3.67 % | $ 14.8 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.6 B | $ 674.78 | -0.29 % | $ 55.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 28.73 | -1.79 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
5.39 B | $ 132.75 | -0.37 % | $ 40.4 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.39 | 0.21 % | $ 5.49 M | USA |